Financial Performance - The company's operating revenue for Q3 2023 was ¥98,499,939.26, representing a year-on-year increase of 6.38%[3] - Net profit attributable to shareholders for Q3 2023 reached ¥4,692,230.29, a significant increase of 569.12% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥4,098,404.48, reflecting a remarkable increase of 3,860.00% year-on-year[3] - The basic earnings per share for Q3 2023 was ¥0.0124, up 552.63% from the previous year[3] - Total operating revenue for the first three quarters of 2023 reached ¥265,713,871.38, a 3.3% increase from ¥256,357,915.51 in the same period of 2022[16] - Net profit for the first three quarters of 2023 was ¥17,691,786.72, representing a 60.5% increase compared to ¥10,995,714.37 in the same period of 2022[17] - The company reported a basic earnings per share of ¥0.0468, up from ¥0.0293 in the same period last year[18] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥1,044,336,508.26, an increase of 4.29% compared to the end of the previous year[4] - As of September 30, 2023, total assets amount to RMB 1,044,336,508.26, an increase from RMB 1,001,329,612.78 at the end of 2022[14] - The total liabilities as of September 30, 2023, are RMB 335,489,596.97, compared to RMB 334,306,129.32 at the end of 2022[14] - The company's equity attributable to shareholders is RMB 708,846,911.29, up from RMB 667,023,483.46 at the end of 2022[14] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥14,028,601.63, down 32.84% year-on-year[3] - Cash flow from operating activities generated a net amount of ¥14,028,601.63, down from ¥20,888,519.77 in the same period last year[20] - Cash flow from investing activities showed a net outflow of ¥102,037,195.22, compared to a net outflow of ¥52,843,752.99 in the previous year[20] - Cash flow from financing activities resulted in a net inflow of ¥16,333,538.46, compared to a net outflow of ¥90,575.10 in the same period of 2022[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,134[9] - Xinjiang Hualing Industrial Trade (Group) Co., Ltd. holds 20.88% of shares, making it the largest shareholder[10] - The number of stock options exercised during the period was 2,727,957 shares, increasing the total share capital to 380,951,412 shares[11] Expenses and Investments - Total operating costs decreased to ¥220,178,994.04, down 3.9% from ¥228,141,629.17 year-on-year[16] - Research and development expenses increased to ¥21,203,663.30, up 22.5% from ¥17,282,320.53 in the previous year[16] - The company reported a decrease in financial expenses for the year-to-date by 590.69%, attributed to increased interest income from higher deposit amounts[7] Other Financial Metrics - The weighted average return on equity for the year-to-date was 2.61%, an increase of 1.01 percentage points compared to the previous year[3] - The company's total assets impairment loss was ¥25,453,218.80, compared to ¥12,607,678.69 in the previous year, indicating increased asset challenges[17] - The company's cash and cash equivalents decreased to RMB 64,055,590.14 from RMB 135,730,645.27 year-over-year[12] - Accounts receivable increased to RMB 24,864,056.88 from RMB 19,352,180.88 year-over-year, indicating a growth of approximately 28.0%[13] - Inventory decreased to RMB 139,136,791.82 from RMB 149,425,813.82, a decline of about 6.9%[13] - The company reported a net loss of RMB 1,940,257,555.53 in retained earnings as of September 30, 2023[14]
百花医药(600721) - 2023 Q3 - 季度财报